A股又一天价离婚案，女方分走超5亿，中国巴菲特失去实控权

Core Viewpoint - The divorce property dispute between Zhao Bingxian and Lu Juan, which lasted for 15 years and involved significant assets and control over listed companies, has reached a final judgment, resulting in a change of actual control over WoHua Pharmaceutical [1][3]. Group 1: Legal Proceedings and Control Changes - The court ruled that Zhao Bingxian and Lu Juan will each hold 50% of the shares in Zhongzheng Wanrong Investment Group, the controlling shareholder of WoHua Pharmaceutical, leading to a situation where WoHua Pharmaceutical has no actual controller [3][9]. - The value of the shares transferred to Lu Juan is approximately 547 million yuan, based on WoHua Pharmaceutical's market capitalization of 3.648 billion yuan as of November 10, 2025 [3][9]. - Lu Juan expressed that the equal division of shares would prevent a single major shareholder from dominating the company, promoting healthier development [3][12]. Group 2: Company Background and Performance - WoHua Pharmaceutical, established in 2002 and listed in 2007, specializes in the research, production, and sales of natural plant-based cardiovascular traditional Chinese medicine [11]. - The company's core products, including WoHua Xinkeshu tablets and Bone Shu Kang capsules, are the main sources of revenue and profit [11]. - The company has faced declining performance, with net profit decreasing for four consecutive years from 2021 to 2024, largely due to price reductions and high marketing costs [11][12]. Group 3: Future Outlook and Management - Despite the challenges, WoHua Pharmaceutical showed signs of recovery in 2025, with a reported revenue of 625 million yuan, an increase of 8.31% year-on-year, and a net profit of 63.995 million yuan, up 179.34% [11][12]. - Lu Juan plans to actively participate in company decision-making and governance following the share division, emphasizing the importance of a professional management team and sound internal governance for sustainable development [12][13].